VOLUME 16 | NUMBER 11 | NOVEMBER 2013 nature neuroscience r e v i e w Many forms of long-term synaptic and spine morphological plasticity require rapid protein synthesis for their expression, whereas the requirement for new transcription is temporally delayed, suggesting that the translation of existing mRNAs is fundamental to the expression of synaptic plasticity 1 . One of the most intriguing examples of a disease characterized by defects in complex behavior and cognition in humans, and defects in synaptic plasticity and circuit function in mouse models, is FXS, which is caused by a loss of function of the RNA-binding protein FMRP (reviewed in refs. 2,3). Mouse models of FXS are characterized by widespread defects in synaptic plasticity 4 , and both mice and humans have been found to have increased numbers of long, thin dendritic spines relative to the mushroom-shaped spines that are characteristic of stronger, more mature synapses 5, 6 . Recent studies have revealed marked alterations in spine dynamics, including an accelerated turnover rate and a failure to respond to input 7, 8 . Notably, several protein synthesis-dependent forms of plasticity lose their dependence on new translation in the absence of FMRP 9,10 , suggesting that plasticity-related proteins are already present in adequate levels. Plasticity and spine dynamics are essential for establishing and maintaining normal synaptic communication and for supporting larger groups of neurons that function together in circuits linked by these synaptic contacts. Defects in several neuronal circuits have been described that result from the absence of FMRP 11 . These studies underscore the importance of FMRP for normal brain function.
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Elucidating FMRP function at the molecular level is important for unraveling its role in more complex processes at the level of synapses, circuits and behavior. FMRP is expressed in all neurons, but not in mature glia 12 . In neurons, FMRP is enriched in the cell body, although some is present in granules in dendrites and axons during development 13 . The vast majority of FMRP is associated with polyribosomes 14, 15 in complexes that contain several stalled ribosomes in addition to its target mRNAs 16 . The primary function of FMRP is to repress translation of specific mRNAs, and it is widely believed that the loss of this form of translational control leads to the deficits seen in human FXS patients and disease models. However, more global effects on translation may be a secondary consequence of dysregulation of the primary mRNA targets of FMRP. Thus, elucidating the molecular details of the function of FMRP in regulating translation and identifying the primary and secondary changes in protein expression that result from its absence are of critical importance. In addition, understanding the activity-dependent mechanisms by which FMRP is regulated is critical for understanding both the pathology of FXS and the manner in which protein synthesis regulates synaptic strength in healthy neurons. This review focuses on presenting and evaluating recent experiments addressing these issues and how recent progress might inform therapeutic development for treatment of individuals with FXS.
FMRP as a translational regulator
Shortly after the human FMR1 gene was cloned 17 , it was recognized that the encoded protein, FMRP, harbors three canonical RNA binding domains 18 . Although almost all cases of FXS are caused by a complete loss of expression of FMRP resulting from transcriptional silencing, a single patient exists with a point mutation in the second KH domain (KH2) that converts a key hydrophobic amino acid in the heart of the RNA-binding pocket to a bulky charged group, referred to as I304N 19, 20 . Polysome fractionation of I304N FXS lymphoblastoid cells 21 and brain from an I304N knock-in mouse model 22 revealed that the function of the KH2 RNA-binding domain is essential for normal polyribosome association of FMRP. Furthermore, characterization of endogenous I304N-FMRP in mouse brain demonstrated that the mutation results in the loss of RNA binding by FMRP 22 , strongly suggesting that the association of FMRP with polysomes, mediated by RNA binding, is a critical aspect of its function. Coupled with studies demonstrating that impaired memory in an FXS model can be r e v i e w rescued using translational inhibitors 23 , it is likely that understanding translational control by FMRP will inform both the disease and normal neuronal biology.
Mammalian KH domains adopt a very consistent fold that is necessary for sequence-specific recognition of single-stranded RNA motifs of 4-7 nucleotides 24 . Given that FMRP harbors two KH domains, one of which (KH2) binds with high affinity to an RNA ligand with both sequence and structural determinants 25 , coupled with reports of the association of FMRP with a subset of mRNAs 26, 27 , it seems likely that FMRP binds to specific RNA targets through these motifs. The pursuit of this putative set of FMRP-specific mRNA targets has been reviewed elsewhere 28 , but has recently culminated in surprising findings.
The mRNA targets of FMRP Recent studies have identified in vivo RNA-binding sites for RNAbinding proteins using ultraviolet irradiation to capture endogenous interactions by introducing a covalent crosslink between the protein and bound RNA 29 . After reducing the size of the bound RNA 'tags' , the RNA-binding protein:RNA complex can be stringently purified, usually by immunoprecipitation, and the small RNA ligands cloned and sequenced by high-throughput methods. Application of this technique to capture RNA binding by FMRP in mouse brain was performed at postnatal days 11-25, a critical period for plasticity. This analysis identified a robust set of 842 FMRP target mRNAs that were markedly enriched in both pre-and postsynaptic proteins 16 .
The postsynaptic targets of FMRP include about 30% of the postsynaptic density (PSD) proteome and include NMDA receptor (NMDAR) subunits, the mGluR5 receptor, and many proteins that comprise the NMDA and mGluR5 receptor interactomes 16 . For example, the NMDAR subunits NR1, 2A, 2B and 3A, PSD-93 and PSD-95, SAPAP1-4, Shank1-3, Homer1, SynGAP1, and neuroligins 1-3 are FMRP targets. In contrast, FMRP does not appear to regulate expression of the AMPA receptor interactome. None of the four AMPA receptor subunits, the eight members of the stargazin-TARPCacng family, cornichon homologs (Cnih2/3), Shisa9 (also known as CKAMP-44), EphrinB2 or the newly identified Gsg1L 30 are FMRP targets. This is one example of selective mRNA regulation by FMRP to control expression of specific complexes and pathways in neurons that may have important consequences for synaptic function.
Postsynaptic targets of FMRP were expected on the basis of synaptic plasticity deficits and the localization of FMRP to dendrites, as observed by electron microscopy; however, the observation that FMRP may also regulate as much as 30% of the presynaptic proteome was surprising. This includes the large scaffolding proteins bassoon and piccolo, the neurexin family of cell surface adhesion molecules, synapsins 1 and 2, the synaptic vesicle glycoproteins SV2A and SV2B, subunits of the clathrin-associated adaptor complex AP-2, synaptotagmins 1, 7 and 11, unc13, the syntaxin-binding proteins 1 (unc18) and 5 (tomosyn), SNAP-25, and many voltage-gated calcium channels. In addition, several kinesins, which deliver cargo to presynaptic terminals, are FMRP targets (Kif1a, Kif1b, Kif1c, Kif5a, Kif5c, Kif3, Kif21a and Kif21b). A presynaptic role for FMRP (reviewed in ref. 31 ) is supported by recent studies in hippocampus [32] [33] [34] , cortex 35 and amygdala 36 . A need for rapid synthesis of presynaptic proteins for the formation and maintenance of new synapses has been elegantly described 37 . The recent report of enhanced vesicle recycling and enlarged readily releasable and reserved vesicle pools found at CA3-CA1 synapses in Fmr1 knockout mice 33 is therefore consistent with the idea that FMRP might normally limit these processes by repressing presynaptic protein synthesis. The presence of FMRP in presynaptic or axonal FMRP-containing granules supports this model 13, 38 .
A role for a general translational increase in FXS Although FMRP directly regulates the translation of a specific subset of target mRNAs, several studies have demonstrated that secondary alterations in general translation may accompany the primary changes that directly result from loss of FMRP association with specific mRNAs. Studies using rabbit reticulocyte lysate assays have shown that FMRP causes a dose-dependent inhibition of the translation of brain poly(A) RNA 39, 40 , and translation is increased in cortical synaptoneurosome preparations from Fmr1 knockout mice, as assayed by 35 S-methionine labeling 41, 42 . These in vitro studies are supported by several types of protein synthesis assays in cell cultures from FXS patients and brain slices from Fmr1 knockout mice 41, 43, 44 . Perhaps more importantly, in vivo studies with L-[1-14 C] leucine have shown that Fmr1 knockout mice exhibit increased rates of brain protein synthesis 45 .
It is impossible to ascertain whether the increased protein synthesis is exclusively a result of the release of translational repression on specific FMRP targets. However, the magnitude of the increased protein synthesis seems inconsistent with an exclusive translation of FMRP target mRNAs. FMRP target mRNAs represent about 5% of all mRNAs and are not particularly abundant; mRNAs for abundant housekeeping genes and ribosomal proteins are not generally associated with FMRP 16 . Moreover, FMRP is not expressed in mature glia and should therefore not directly affect protein synthesis in these cells, which may explain why increased protein synthesis is more apparent in areas of high neuronal cell body density relative to glia 45 . Thus, the increase in translation of specific FMRP target mRNAs as a result of its absence would have to be substantial to comprise 25% of all new protein synthesis.
Suggestions of specificity in increased protein synthesis do exist; radio-immunoprecipitation assays in labeled hippocampal slices have shown a 25% increase in target CaMKIIα synthesis with no change in the non-target GAPDH 46 . Once again, however, the magnitude of this increase appears to be inadequate to explain the increased protein synthesis in Fmr1 knockout mice, which suggests that a global increase in translation as a result of long-term loss of FMRP may be a secondary outcome of loss of direct repression. In support of this possibility, no global increase in 35 S-methionine incorporation was observed as a result of acute loss of polysome association by all three FXRP family members using an RNA decoy approach, despite specific increases in FMRP targets 16 . In addition, it is notable that FMRP normally represses expression of NMDARs and mGluR5 receptors, scaffolding proteins, and several components of the downstream extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) pathways, as well as several potentially limiting initiation and elongation factors. Excess production of these and other proteins in the absence of FMRP could lead to secondary increases in protein synthesis.
Outcome of loss of translational repression
Once a high-confidence list of FMRP mRNA targets and an equally robust list of non-targets controlled for length and neuronal abundance were identified, it was possible to link mRNA binding with a functional outcome. A brain polyribosome-programmed in vitro translation system quantitatively revealed that ribosome stalling occurs on FMRP target transcripts 16 (Fig. 1) . Two genetic models for FMRP loss of function and an acute loss-of-function model were used to demonstrate that the absence of FMRP results in relief of ribosome stalling and increased synthesis of the target proteins. Thus, the simplest model predicting the outcome of loss of translational repression by FMRP in vivo is an increase in the synthesis of its specific mRNA npg r e v i e w targets resulting in higher than normal levels of the encoded proteins, although compensatory mechanisms such as turnover may restore normal levels of some of the proteins. Because increased levels of proteins are not always pathogenic, it is necessary to identify which of the many target proteins contribute to FXS pathogenesis. A logical first step is to use either western blot or a more global proteomic approach to identify protein level changes in FXS models. Many such experiments have been performed with often-conflicting results, including reports of decreased levels of FMRP targets. Here we review this data in light of the idea that an increase in global protein synthesis may accompany loss of FMRP.
Western blots have been used to detect increases in FMRP target proteins in its absence. Perhaps the best example of this is the FMRP target MAP1B. In Fmr1-null flies that have only one FMRP paralog, a robust bidirectional regulation in MAP1B levels is evident as a result of a loss or overexpression of Fmr1 (ref. 47 ). In mice, in which three potentially redundant paralogs exist, a 75% increase in MAP1B is observed in Fmr1 knockout hippocampal slices 10 and a 30% increase is seen in total brain extract 48 . Increased levels of other FMRP target proteins also have been observed in mice, including CaMKIIα 10,48 , striatal-enriched protein tyrosine phosphatase (STEP) 49 , the potassium channels Kv3.1 (ref. 50) and Kv4.2 (ref. 51) , and the upstream regulator of phosphoinositide 3 kinase (PI3K), PI3K enhancer (PIKE) 52 . Examination of 17 known PSD proteins in purified PSD preparations revealed that many FMRP targets are increased at either 2 weeks or 2 months of age in either neocortex or hippocampus including SAPAPs 1-3 (dlgap1-3), Shanks 1 and 3, and NMDAR subunits 53 . In human samples, the target CYFIP2 was increased in FXS patients relative to normal controls 54 .
However, in many cases, steady-state levels of FMRP target proteins appear to be unchanged in the absence of FMRP. Although this might be explained by the age or tissue examined (see examples in refs. 12,53), activation state, or increased protein turnover that offsets increased synthesis, recent examples of apparently decreased levels of FMRP targets (an 8-15% decrease in FMRP targets NR1, NR2A, NR2B and SAPAP3 (ref. 55 ), a decrease in SYNGAP1 and NR2B 12 ), as well as altered levels of non-targets, further muddy the correlation between association of an mRNA with FMRP and increased protein synthesis in FMRP's absence. These findings underscore the importance of complementary proteomic approaches in understanding the functional outcome of FMRP loss of function.
FMRP-bound mRNAs suggest new therapeutic targets for FXS
High-throughput methods, including high-throughput sequencing of RNAs isolated by crosslinking and immunoprecipitation, have demonstrated that RNA-binding proteins can regulate functionally related sets of target RNAs in the mammalian nervous system 29 . Ingenuity functional pathway analysis suggests that this is also true for the FMRP-regulated target transcripts 16 . Such analysis may be of special benefit, considering that components of these pathways may be overexpressed in FXS, focusing efforts on their inhibition. Pathway analysis suggests that glutamate receptor signaling and synaptic plasticity might be affected by loss of FMRP. These findings are consistent with and extend reports that, in the absence of FMRP, protein synthesis is exaggerated 56 such that either genetic or pharmacologic inhibition of mGluR5 rescues phenotype in Fmr1 knockout mice 43, 57 and mGluR5 show evidence of clinical efficacy 58 . In addition to mGluR antagonists, the identification of the NMDAR pathway as an FMRP target is significant, as NMDAR antagonists are available that might be considered for clinical evaluation either as single agents or in conjunction with mGluR5 antagonists. mGluRs and NMDARs mediate changes in synaptic plasticity by signaling through the PI3K-Akt-mTORC1 and MEK-ERK pathways to increase cap-dependent translation 59 . Recent data suggests that FMRP may also regulate the activity of these translational control pathways directly. For example, the sixth ranked FMRP target is PIKE (also known as centaurin-γ1), which is overexpressed in the Fmr1 knockout mouse, resulting in elevated PI3K signaling to the mTORC1 pathway 52 . Moreover, FMRP target mRNAs include several that encode the protein products of negative regulators of mTORC1 signaling, including phosphatase and tensin homolog deleted from chromosome 10 (PTEN), neurofibromatosis 1 (NF1) and tuberin (TSC2), suggesting a critical role for FMRP in regulating the balance of cap-dependent translation. In addition, ERK1, all three eIF4G isoforms, eEF2 and eEF1α, Ago1/2, and Dicer are FMRP targets. Thus, it is possible that loss of FMRP may have secondary effects on neuronal translation. These findings add support to the idea that pharmacologic agents that act on the mTORC1 and ERK pathways may be worth considering therapeutically 60, 61 .
FMRP target mRNAs also encode proteins involved in the regulation of cAMP levels, including adenylate cyclases and phosphodiesterases 16 . These findings are consistent with observations that Fmr1-null flies, Fmr1 knockout mice 62 and human patients 63 have altered basal or stimulated cAMP levels. In addition, a large number of proteins regulating small GTPases are targeted by FMRP, including at least 11 GTPase activating proteins and 12 guanine nucleotide exchange factors. The striking enrichment of these proteins as FMRP targets is significant, as some have been found to regulate the actin cytoskeleton in an activity-dependent manner in neurons 64 , and perturbing their function alters dendritic spine morphology and is linked with neurologic disease 65 . A prominent example is the target SYNGAP1, which is stimulated by NMDARs to regulate ERK 66 and is both a cause of non-syndromic mental retardation and strongly linked to autism 67 . Minocycline, a tetracycline analog (orange spheres), and many other small molecules inhibit translation by interfering with ribosomal translocation in different ways. Because of the similarity in proposed action between FMRP and such small molecules, it is possible that they might partially replace FMRP functions lost in FXS and be therapeutically beneficial.
npg r e v i e w
Receptors that regulate FMRP as therapeutics for FXS Experiments examining synaptic plasticity in Fmr1 knockout mice were the first to identify potential molecular targets for therapeutics to treat individuals with FXS. The initial studies largely focused on protein synthesis-dependent forms of long-lasting synaptic plasticity because of the role of FMRP as a translational repressor. The first breakthrough was the finding that hippocampal mGluR-dependent long-term depression (LTD), which requires dendritic protein synthesis 68 , is enhanced in Fmr1 knockout mice 69 . This gave rise to the mGluR theory 56 , which posited that abnormal synaptic function and aberrant behavior in FXS is a result of exaggerated mGluR-dependent protein synthesis. Consistent with this theory, developmental defects and aberrant behavior in Fmr1 flies is reversed by the mGluR5 antagonist MPEP 70 . Moreover, genetic reduction of mGluR5 has been shown to correct abnormal dendritic spine morphology, exaggerated protein synthesis, enhanced mGluR LTD and behavioral phenotypes displayed by Fmr1 knockout mice 43 . More recently, it was shown that acute treatment of young adult Fmr1 knockout mice with the selective mGluR5 inhibitor CTEP can reverse exaggerated protein synthesis, enhanced mGluR LTD and susceptibility to audiogenic seizures, and chronic treatment reverses abnormal dendritic spine morphology and cognitive deficits 57 . These studies are particularly important when considering therapeutic treatments for FXS individuals, as CTEP corrected FXS-associated phenotypes after their onset. There are numerous other examples demonstrating that blocking group I mGluRs can correct a broad array of neuronal, synaptic and behavioral phenotypes associated with FXS 2 . Fmr1 knockout mice also have impaired GABA receptor function that is likely caused by decreased expression of GABA A receptor subunits and/or enzymes that synthesize GABA [71] [72] [73] , suggesting that inhibitory synaptic transmission is decreased in FXS. Indeed, in Fmr1 null flies, GABA treatment rescued multiple phenotypes, including abnormal behavior 74 , and it was recently shown that GABA A receptor agonists reduce audiogenic seizures in Fmr1 knockout mice 75 . Moreover, exaggerated protein synthesis, susceptibility to audiogenic seizures and repetitive behavior are normalized in Fmr1 knockout mice treated with arbaclofen, a GABA B receptor agonist 76 . These studies are particularly intriguing because they have been translated to FXS individuals, in which arbaclofen treatment improved social avoidance, one of the main clinical symptoms of the syndrome 77 . It remains to be determined whether GABA B receptor agonists can reverse FXS-associated phenotypes via the dampening of excessive mGluR5-mediated protein synthesis.
The therapeutic targets for FXS mentioned above are neurotransmitter receptors, which are the most common targets for the treatment of neurological and psychiatric disorders. The advantage of targeting neurotransmitter receptors is that there are likely to be fewer peripheral side effects in individuals treated with the compounds. However, G protein-coupled receptors such as group I mGluRs regulate a plethora of downstream neuronal signaling pathways in the brain, and receptor-targeted compounds could therefore inhibit pathways that are not affected in FXS individuals. Recent studies have begun to delineate the signaling pathways that couple group I mGluRs to the translation machinery, providing a new set of potential therapeutic targets for treatment of FXS.
Translational control molecules as therapeutics for FXS
Two protein kinase signaling pathways that regulate translation initiation, mTORC1 and ERK, have been implicated in the pathophysiology of FXS. mTORC1 phosphorylates eIF4E-binding protein (4E-BP) and p70 S6 kinase 1 (S6K1), both of which bind Raptor 78 .
Unphosphorylated 4E-BP binds tightly to eIF4E, whereas 4E-BP phosphorylated by mTORC1 does not, thereby permitting eIF4E to bind eIF4G and form the eIF4F initiation complex, which allows initiation to proceed. mTORC1 also affects initiation by phosphorylating S6K1, which then phosphorylates downstream targets, such as ribosomal protein S6 and eIF4B. Notably, phosphorylation of eIF4B by S6K1 increases the helicase activity of eIF4A, as does the interaction of eIF4E with eIF4G. ERK phosphorylates the kinase, Mnk1, that subsequently phosphorylates eIF4E, which is correlated with enhanced translation (Fig. 2a and refs. 79,80) .
It was reported that Fmr1 knockout mice exhibit increased eIF4E-eIF4G interactions and phosphorylation of S6K1 in the hippocampus 52 , which is indicative of excessive mTORC1 signaling. What is the upstream signaling that couples mGluR5 to mTORC1? It appears to involve disrupted Homer scaffolds and increased PI3K signaling. In Fmr1 knockout mice, mGluR5 is less associated with long Homer isoforms and more associated with the shorter Homer1a 81 . In addition, genetic deletion of Homer1a in Fmr1 knockout mice reduces increased eIF4F complex formation, exaggerated protein synthesis and susceptibility to audiogenic seizures 81 . Interestingly, Homer interacts with PIKE, which, as mentioned above, is an FMRP target mRNA 16 and whose protein expression is increased in Fmr1 knockout mice 41, 52 . Moreover, the expression of the p110β subunit of PI3K, which is also an FMRP target mRNA 16 , is elevated in Fmr1 knockout mice. Inhibitors of PI3K correct exaggerated protein synthesis and abnormal dendritic spine morphology in Fmr1 knockout mice 41 , as well as exaggerated protein synthesis in lymphoblastoid cells from FXS patients 42 . All together, these findings indicate that disrupted Homer scaffolds and excessive PI3K signaling contribute to exaggerated protein synthesis, as well as to molecular, cellular and behavioral phenotypes in FXS.
Because PI3K is typically an upstream regulator of mTORC1 (ref. 60 ), one might predict that disruption of mTORC1 would correct multiple aspects of FXS. However, acute treatment with rapamycin to disrupt mTORC1 does not correct the exaggerated protein synthesis and audiogenic seizures displayed by Fmr1 knockout mice 46 . In contrast, it was recently demonstrated that genetic deletion of S6K1 can correct exaggerated protein synthesis, enhanced mGluR LTD and several behavioral phenotypes displayed by Fmr1 knockout mice 44 . How can one reconcile these seemingly contradictory findings? A simple explanation is that chronic treatments of Fmr1 knockout mice with rapamycin are required to reduce exaggerated protein synthesis. Because both PIKE and the p110β subunit of PI3K are elevated in Fmr1 knockout mice, it is likely that PIKE-PI3K triggers the excessive activation of PDK1 and PDK2 and, subsequently, mTORC1 (Fig. 2) . However, in addition to mTORC1, S6K1 receives input from PDK1 (ref. 82 ) and ERK 79 . Thus, S6K1 activity could be stimulated by either PDK1 or ERK; the former being consistent with the observation of elevated PIKE-p110β levels in FXS mice 52 and the latter being consistent with the observation that hypersensitivity to ERK contributes to exaggerated protein synthesis and audiogenic seizures in Fmr1 knockout mice 46 . Moreover, lovastatin, which interferes with Ras activation, was recently shown to prevent ERK activation, exaggerated protein synthesis and susceptibility to audiogenic seizures in Fmr1 knockout mice 83 . Thus, S6K1 is a potential integrator of signaling from both increased levels of PI3K and hypersensitivity to ERK in FXS (Fig. 2b) .
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either hamartin (TSC1) or TSC2 (ref. 84) . Because inactivation of TSC1 and TSC2 upregulates mTORC1 signaling, one would predict that TSC model mice, similar npg r e v i e w to Fmr1 knockout mice, would exhibit enhanced translation. However, it was shown that TSC2 mutant mice have decreased translation in the hippocampus that can be blocked by rapamycin 85 , which is likely a result of feedback inhibition of pathways upstream of mTORC1 (ref. 60 ) and/or upregulation of the unfolded protein response 86 . Moreover, the TSC model mice, in contrast to Fmr1 knockout mice, displayed impaired mGluR LTD. Finally, when TSC model mice were bred with Fmr1 knockout mice, protein synthesis, mGluR LTD, and cognitive phenotypes that were present in both lines of mutant mice were normalized 85 . As mentioned earlier, TSC2 mRNA is a target of FMRP 16 , so it is possible that TSC2 protein expression is altered in Fmr1 knockout mice. An additional unknown is the molecular signaling responsible for the normalization of the phenotypes displayed by the TSC-FXS double mutant mice.
The mRNAs that encode PIKE, PI3K and TSC2 are all associated with FMRP and their protein products are therefore potential therapeutic targets for FXS (Fig. 2b) . Other signaling molecules that may be targets include STEP 49 and GSK3β 87, 88 , whose transcripts are also FMRP targets 16 . Thus, downstream signaling pathways that are affected by the reduction of STEP and GSK3β and whether they interact with the mTORC1 and ERK pathways in FXS remains to be elucidated.
The idea that the lack of FMRP results in exaggerated mGluRdependent protein synthesis is the leading theory for the molecular basis of FXS, and both genetic reduction 43 and pharmacological inhibition of mGluR5 (ref. 57) reduce exaggerated protein synthesis and a broad range of phenotypes displayed by Fmr1 knockout mice. However, it has been reported that mGluR LTD is protein synthesisindependent in Fmr1 knockout mice 9, 10 . Moreover, activation of group 1 mGluRs is uncoupled from the activation of PI3K 41, 89 , mTORC1 (refs. 52,81,89) and ERK 10 , the translation of FMRP target mRNAs, including MAP1B 10 , p110β 41 and STEP 49 , the translation of Arc 81 , and general protein synthesis 41, 46 . These findings suggest that the loss of FMRP limits the dynamic range for mGluR-dependent protein synthesis and that dampening mGluR-dependent translational control, via either an mGluR antagonist or by targeting downstream effectors such as PI3K and S6K1, is required to reset translational homeostasis in Fmr1 knockout mice (Fig. 2b) .
Novel therapy for FXS directed at FMRP function
Although targeting signaling pathways has the advantage of being downstream of neurotransmitter receptors, many of these kinases, including PI3K and ERK, are still far enough upstream from the translational machinery that their inhibition could affect signaling cascades that are unaffected in FXS. Thus, if excessive translation of FMRP target mRNAs and/or exaggerated general protein synthesis is the causative factor in FXS, then the direct targeting of the translational machinery might be the most effective way to reset translational homeostasis. Evidence for the efficacy of this approach was first provided by studies in Fmr1-null flies, which found that the general protein synthesis inhibitors cycloheximide and puromycin rescue impaired long-term memory 23 . Thus, direct targeting of the translational machinery may be a means for reversing abnormal behaviors associated with FXS.
There is speculation that exaggerated translation is causative not only for FXS, but also for other autism spectrum disorders (ASDs) 60, 61 , and there is evidence for a genetic link between ASD and the cap-binding translation initiation factor eIF4E 90 . Moreover, microdeletions in the Prader-Willi-Angelman critical region contain the gene encoding CYFIP1, a non-canonical 4E-BP that also binds to FMRP 91 . Notably, it was recently shown that transgenic mice overexpressing eIF4E exhibit increased eIF4F complex formation, exaggerated protein synthesis, enhanced mGluR-LTD in the striatum and hippocampus, and aberrant autistic-like behaviors, all of which were reversed by 4EGI-1, an inhibitor of eIF4E-eIF4G interactions 92 . These findings provide direct evidence for the idea that exaggerated protein synthesis can cause synaptic and behavioral aberrations associated with ASD. Moreover, because Fmr1 knockout mice exhibit increased eIF4E-eIF4G interactions 52, 81 , these findings suggest that exaggerated protein synthesis, enhanced mGluR LTD and FXS-associated behaviors in Fmr1 knockout mice might be reversible by 4EGI-1.
As discussed above, FMRP functions to stall ribosomal translocation on its target mRNAs, suggesting that compounds that inhibit translation elongation might alleviate phenotypes associated with the loss of FMRP (Fig. 1) . Many small molecules, primarily used as antibiotics because they stall the translocation of bacterial ribosomes, have already been tested in relevant assays. Interestingly, minocycline, a second generation tetracycline analog, reverses abnormal synaptic structure, spine morphology and aberrant behaviors exhibited by Fmr1 knockout mice 93 and Fmr1 null flies 94 . Minocycline was tested in these models because it inhibits matrix metalloproteinase-9 Green arrows indicate either total or phosphorylated levels (indicated by red P) of proteins that have been reported to increase in either FXS model mice or cells from FXS individuals 41, 42, 44, 48, 49, 52, 54, 81 . Proteins with red lines around them indicate those that have been successfully targeted either pharmacologically or genetically to reverse molecular, cellular, morphological, synaptic and/or behavioral phenotypes in animal models of FXS 41-44,46,49,52,57,70,74,81,83 . npg r e v i e w (MMP-9), which is overexpressed in Fmr1 knockout mice 93 and flies 94 . However, one has to wonder whether all or part of the effect of minocycline is a result of its ability to slow down ribosomes, taking the edge off excess translation, as previously suggested 16 .
Minocycline is an antibiotic used in humans that is quite lipid soluble and crosses the blood-brain barrier well 95 . Minocycline and other tetracycline molecules inhibit protein synthesis via A-site occupation and stall mammalian ribosomes with 7-20% of the efficacy with which they inhibit bacterial translation 96 . Preliminary open-label add-on clinical trials with minocycline have shown positive results for cognitive and behavioral measures in 20 FXS patients 97 , which warrants further research on minocycline and other inhibitors of ribosomal elongation.
Summary and conclusions
Knowledge concerning the function of FMRP and how its loss alters receptor-mediated signaling and translational control leading to aberrant dendritic spine dynamics, synaptic plasticity, circuit function and complex behavior in FXS has expanded exponentially in the last decade. Nonetheless, questions central to the development of therapeutics for treating individuals with FXS remain unanswered. Traditional methods of drug discovery for brain disorders focus on neurotransmitter receptors with good reason, and there is considerable optimism that pharmaceuticals targeting metabotropic glutamate receptors and GABA receptors will provide benefits for FXS patients. In addition, the identification of the mRNA targets of FMRP that encode synaptic proteins and components of signaling pathways involved translational control, many of which overlap with autism and other neurodevelopmental disorders, have provided a rich list of potential therapeutic targets for FXS. However, this plethora of targets implies that one should be very cautious in inferring the normal function of FMRP from studying the chronic loss-of-function state in Fmr1 mutant animals and cell lines from individuals with FXS. We argue that the main function of FMRP is to regulate protein synthesis and, as such, FXS should be considered a disease of dysregulated translation. Finally, because the lack of FMRP appears to alter the expression of a multitude of proteins involved in translational control and synaptic function, we propose that a rational approach for effective treatment of FXS would be to reset translational homeostasis by targeting initiation and/or elongation, thereby translating translation to the clinic. In the version of this article initially published online, a section heading read "Novel therapy for FXS directed at its molecular function. " The correct heading is "Novel therapy for FXS directed at FMRP function. " The error has been corrected for the print, PDF and HTML versions of this article.
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